HLS Therapeutics Inc (HLTRF) (Q3 2026) Earnings Call Highlights: Cardiovascular Surge Offsets ...
HLS Therapeutics Inc (HLTRF) posted 5% revenue growth to $14.2 million as its cardiovascular portfolio climbed 21%, Nilemdo patient starts accelerated, and debt fell 17%, though adjusted EBITDA Related Stocks: HLTRF ,